118 related articles for article (PubMed ID: 8093910)
1. Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression.
Carroll PR; Waldman FM; Rosenau W; Cohen MB; Vapnek JM; Fong P; Narayan P; Mayall BH
J Urol; 1993 Feb; 149(2):403-7. PubMed ID: 8093910
[TBL] [Abstract][Full Text] [Related]
2. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.
Cher ML; Chew K; Rosenau W; Carroll PR
Prostate; 1995 Feb; 26(2):87-93. PubMed ID: 7855002
[TBL] [Abstract][Full Text] [Related]
3. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.
Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H
Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072
[TBL] [Abstract][Full Text] [Related]
4. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder.
Waldman FM; Carroll PR; Cohen MB; Kerschmann R; Chew K; Mayall BH
Mod Pathol; 1993 Jan; 6(1):20-4. PubMed ID: 8093979
[TBL] [Abstract][Full Text] [Related]
5. Comparison of proliferating cell nuclear antigen versus the more standard measures of rectal mucosal proliferation rates in subjects with a history of colorectal cancer and normal age-matched controls.
Einspahr J; Alberts D; Xie T; Ritchie J; Earnest D; Hixson L; Powell M; Roe D; Grogan T
Cancer Epidemiol Biomarkers Prev; 1995 Jun; 4(4):359-66. PubMed ID: 7655331
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity of proliferating cell nuclear antigen compared with bromodeoxyuridine incorporation in normal and neoplastic rat tissue.
Wijsman JH; Van Dierendonck JH; Keijzer R; van de Velde CJ; Cornelisse CJ
J Pathol; 1992 Sep; 168(1):75-83. PubMed ID: 1360499
[TBL] [Abstract][Full Text] [Related]
7. Comparison of proliferating cell nuclear antigen (PCNA) staining and BrdUrd-labelling index under different proliferative conditions in vitro by flow cytometry.
Lohr F; Wenz F; Haas S; Flentje M
Cell Prolif; 1995 Feb; 28(2):93-104. PubMed ID: 7893842
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma.
Nemoto R; Kawamura H; Miyakawa I; Uchida K; Hattori K; Koiso K; Harada M
J Urol; 1993 Jan; 149(1):165-9. PubMed ID: 8093265
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bromodeoxyuridine and proliferating cell nuclear antigen labeling in gastric carcinoma.
Kang SM; Kim WH; Kim CW; Kim YI
J Korean Med Sci; 1994 Feb; 9(1):16-20. PubMed ID: 7915118
[TBL] [Abstract][Full Text] [Related]
10. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters.
Harper ME; Glynne-Jones E; Goddard L; Wilson DW; Matenhelia SS; Conn IG; Peeling WB; Griffiths K
Prostate; 1992; 20(3):243-53. PubMed ID: 1374182
[TBL] [Abstract][Full Text] [Related]
11. Proliferating cell nuclear antigen (PCNA): expression in samples of human astrocytic gliomas.
Revesz T; Alsanjari N; Darling JL; Scaravilli F; Lane DP; Thomas DG
Neuropathol Appl Neurobiol; 1993 Apr; 19(2):152-8. PubMed ID: 8100356
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models.
van Weerden WM; Moerings EP; van Kreuningen A; de Jong FH; van Steenbrugge GJ; Schröder FH
Cell Prolif; 1993 Jan; 26(1):67-75. PubMed ID: 8439590
[TBL] [Abstract][Full Text] [Related]
13. The effect of incubation of rectal biopsies on measures of proliferation using proliferating cell nuclear antigen in comparison with 5-bromo-2-deoxyuridine.
Kilias D; Macrae FA; Sharpe K; Young GP
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):819-24. PubMed ID: 9332765
[TBL] [Abstract][Full Text] [Related]
14. Cell proliferation in colorectal adenocarcinomas: comparison between Ki-67 immunostaining and bromodeoxyuridine uptake detected by immunohistochemistry and flow cytometry.
Le Pessot F; Michel P; Paresy M; Lemoine F; Hellot MF; Paillot B; Scotte M; Peillon C; Hemet J
Pathol Res Pract; 2001; 197(6):411-8. PubMed ID: 11432668
[TBL] [Abstract][Full Text] [Related]
15. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder.
Cohen MB; Waldman FM; Carroll PR; Kerschmann R; Chew K; Mayall BH
Hum Pathol; 1993 Jul; 24(7):772-8. PubMed ID: 8100555
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological use of rectal proliferation measures.
Baron JA; Wargovich MJ; Tosteson TD; Sandler R; Haile R; Summers R; van Stolk R; Rothstein R; Weiss J
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):57-61. PubMed ID: 7894325
[TBL] [Abstract][Full Text] [Related]
17. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67.
Taftachi R; Ayhan A; Ekici S; Ergen A; Ozen H
BJU Int; 2005 Mar; 95(4):650-4. PubMed ID: 15705097
[TBL] [Abstract][Full Text] [Related]
18. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining.
van Dierendonck JH; Wijsman JH; Keijzer R; van de Velde CJ; Cornelisse CJ
Am J Pathol; 1991 May; 138(5):1165-72. PubMed ID: 1673821
[TBL] [Abstract][Full Text] [Related]
19. Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators.
Spires SE; Banks ER; Davey DD; Jennings CD; Wood DP; Cibull ML
Urology; 1994 May; 43(5):660-6. PubMed ID: 7909398
[TBL] [Abstract][Full Text] [Related]
20. In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate.
Bocker T; Bittinger A; Wieland W; Buettner R; Fauser G; Hofstaedter F; Rüschoff J
Mod Pathol; 1995 Apr; 8(3):226-31. PubMed ID: 7542384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
